Could a diabetes drug shield Kids' kidneys?
NCT ID NCT07204743
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a drug used in adults for diabetes and kidney protection, can reduce protein leakage in the urine of children with chronic kidney disease. Ten children aged 4 to 18 with persistent proteinuria despite standard therapy will take the drug, and researchers will measure changes in urine protein and kidney function. The goal is to see if the drug can help control the disease and slow kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DAPAGLIFLOZIN (FORXIGA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Al Ahli hospital
Hebron, Palestine, P700, Palestinian Territories
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Diabetes drug shows promise in fighting advanced cancers
- Could a diabetes drug shield kidneys from lupus damage?
- Diabetes drug eye risk under microscope
- Can a common supplement shield dialysis Kids' hearts?
- Could a diabetes drug shield Kids' kidneys? new trial launches
- Pee power: urine test may spare kids painful kidney biopsies